AI Market Mood: Stock Dashboard
XAIR
Fundamental
Company: Beyond Air Inc
Sector: Healthcare
Industry: Medical Devices
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -11.95
Insider Own: 12.33%
Shs Outstand: 4.69M
Perf Week: 6.54%
Market Cap: 11.92M
Forward P/E: -
EPS next Y: -1.06
Insider Trans: 156.10%
Shs Float: 4.58M
Perf Month: -22.97%
Enterprise Value: 17.46M
PEG: -
EPS next Q: -0.96
Inst Own: 10.77%
Short Float: 9.84%
Perf Quarter: -40.00%
Income: -42.12M
P/S: 2.49
EPS this Y: 71.88%
Inst Trans: -41.43%
Short Ratio: 1.70
Perf Half Y: -62.39%
Sales: 4.78M
P/B: 1.08
EPS next Y Percentage: 72.68%
ROA: -112.89%
Short Interest: 0.45M
Perf YTD: -68.20%
Book/sh: 2.12
P/C: 1.80
EPS next 5Y: -
ROE: -323.27%
52W High: 13.52 -83.14%
Perf Year: -75.43%
Cash/sh: 1.27
P/FCF: -
EPS past 3/5Y: 25.75% 17.29%
ROIC: -200.87%
52W Low: 2.02 12.87%
Perf 3Y: -98.75%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - 21.66%
Gross Margin: -24.55%
Volatility W: 5.95%
Volatility M: 7.14%
Perf 5Y: -98.22%
Dividend TTM: -
EV/Sales: 3.65
EPS Y/Y TTM: 63.41%
Oper. Margin: -806.65%
ATR (14): 0.23
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 2.71
Sales Y/Y TTM: 168.20%
Profit Margin: -880.72%
RSI (14): 37.06
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 3.24
EPS Q/Q: 71.15%
SMA20: -11.37%
Beta: 0.28
Target Price: 11.20
Payout: -
Debt/Eq: 1.18
Sales Q/Q: 157.69%
SMA50: -28.11%
Rel Volume: 0.18
Prev Close: 2.25
Employees: 61
LT Debt/Eq: 1.11
Earnings: Aug 12 AMC
SMA200: -60.09%
Avg Volume: 265.57K
Price: 2.28
IPO: Sep 23, 2016
Option/Short: No / Yes
EPS/Sales Surpr.: -24.59% -32.03%
Trades:
Volume: 49,078
Change: 1.33%
Technical:
Latest News:
New AI drug discovery powerhouse Xaira rises with $1B in funding - Fierce Biotech very bullish
XAIR
Summary: Xaira Therapeutics has emerged with $1 billion in committed funding and an impressive team led by prominent figures in the biotech industry, including Marc Tessier-Lavigne, Ph.D., and David Baker, Ph.D. The company aims to revolutionize drug discovery by combining machine learning, data generation, and therapeutic product development.
Full article2024-04-24T14:00:06Z